Back to Search
Start Over
Talimogene laherparepvec in the treatment of melanoma.
- Source :
-
Expert opinion on biological therapy [Expert Opin Biol Ther] 2015; Vol. 15 (10), pp. 1517-30. - Publication Year :
- 2015
-
Abstract
- Unlabelled: : Metastatic melanoma continues to present a significant therapeutic challenge, with an incidence rate rising faster than that of any other cancer. The last 5 years have seen a revolution in the development of new treatments for advanced melanoma, with oncogene targeted agents and checkpoint inhibitor immunotherapies providing the first convincing evidence of a positive shift in overall survival. The role of oncolytic virotherapy in this rapidly evolving field has long been the subject of debate. However, it is with the development of Talimogene Laheparepvec (T-Vec), an intratumourally administered, genetically modified clinical herpes simplex virus-1 strain that has shown positive results in Phase III testing, that the potential for the use of OV may be realised.<br />Areas Covered: This review will outline some of the recent advances in the treatment of advanced melanoma, with a detailed overview of evidence surrounding the development of T-Vec. A literature search was conducted using the databases ‘Medline’ and ‘Pubmed’, including a subsequent manual search of references to identify papers of further relevance.<br />Expert Opinion: As the pivotal OPTiM trial concludes, we outline some of the potential new directions for T-Vec and OV therapy and evaluate the ever-increasing role these novel agents are likely to play in the future landscape of cancer immunotherapy.
- Subjects :
- CD4-Positive T-Lymphocytes immunology
CD4-Positive T-Lymphocytes metabolism
CD8-Positive T-Lymphocytes immunology
CD8-Positive T-Lymphocytes metabolism
Humans
Immunotherapy
Melanoma immunology
Melanoma pathology
Simplexvirus genetics
Simplexvirus metabolism
Melanoma therapy
Oncolytic Virotherapy
Subjects
Details
- Language :
- English
- ISSN :
- 1744-7682
- Volume :
- 15
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Expert opinion on biological therapy
- Publication Type :
- Academic Journal
- Accession number :
- 26629575
- Full Text :
- https://doi.org/10.1517/14712598.2015.1084280